(Bloomberg) -- Moderna Inc. said its experimental vaccine for Covid-19 could be available to a select few as soon as this fall, ahead of expectations for a commercial release in a year.
Stephane Bancel, the biotech's chief executive, told Goldman Sachs on Friday that mRNA-1273 could be made available to a few, potentially health-care workers, under emergency use authorization, according to a company statement. The vaccine was developed in partnership with Moderna and the National Institute of Allergy and Infectious Diseases. Human testing started earlier this month.
A potential vaccine is not expected to be commercially available for at least a year. Moderna is also scaling up manufacturing capacity so it can produce millions of doses each month, the company said.
Moderna's stock rose as much as 2.7% on Monday after a volatile Friday as investors reflected on the 12-month or longer time frame for a new treatment for the virus.
©2020 Bloomberg L.P.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
